160 related articles for article (PubMed ID: 35763699)
1. Timing of Monovalent Vaccine Administration in Infants Receiving DTaP-based Combination Vaccines in the United States.
Marshall GS; Petigara T; Liu Z; Wolfson L; Johnson D; Goveia MG; Chen YT
Pediatr Infect Dis J; 2022 Sep; 41(9):775-781. PubMed ID: 35763699
[TBL] [Abstract][Full Text] [Related]
2. Protective immune responses against Haemophilus influenza type b elicited by a fully-liquid DTaP-IPV-Hib-HepB vaccine (VAXELIS™).
Wilck MB; Jin Xu Z; Stek JE; Goveia MG; Lee AW
Vaccine; 2021 Mar; 39(9):1428-1434. PubMed ID: 33541794
[TBL] [Abstract][Full Text] [Related]
3. Impact of a birth dose of hepatitis B vaccine on the reactogenicity and immunogenicity of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b combination vaccination.
Pichichero ME; Blatter MM; Reisinger KS; Harrison CJ; Johnson CE; Steinhoff MC; Senders SD; Rothstein EP; Willems P; Howe BJ
Pediatr Infect Dis J; 2002 Sep; 21(9):854-9. PubMed ID: 12352809
[TBL] [Abstract][Full Text] [Related]
4. New combination vaccines: DTaP-IPV (Kinrix) and DTaP-IPV/Hib (Pentacel).
Johns TL; Hutter GE
Ann Pharmacother; 2010 Mar; 44(3):515-23. PubMed ID: 20197476
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine.
Pichichero ME; Bernstein H; Blatter MM; Schuerman L; Cheuvart B; Holmes SJ;
J Pediatr; 2007 Jul; 151(1):43-9, 49.e1-2. PubMed ID: 17586189
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States.
Klein NP; Abu-Elyazeed R; Cheuvart B; Janssens W; Mesaros N
Hum Vaccin Immunother; 2019; 15(4):809-821. PubMed ID: 30444673
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine.
Tejedor JC; Moro M; Ruiz-Contreras J; Castro J; Gómez-Campderá JA; Navarro ML; Merino JM; Martín-Ancel A; Roca J; García-del-Río M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Boceta R; García-Corbeira P; Jacquet JM; Collard A; Schuerman L;
Pediatr Infect Dis J; 2006 Aug; 25(8):713-20. PubMed ID: 16874171
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine.
Halperin SA; Tapiéro B; Dionne M; Meekison W; Diaz-Mitoma F; Zickler P; Rubin E; Embree J; Bhuyan P; Lee A; Li M; Tomovici A
Pediatr Infect Dis J; 2014 Jan; 33(1):73-80. PubMed ID: 24346596
[TBL] [Abstract][Full Text] [Related]
9. Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae Type b Conjugate, and Hepatitis B Vaccine, and Guidance for Use in Infants.
Oliver SE; Moore KL
MMWR Morb Mortal Wkly Rep; 2020 Feb; 69(5):136-139. PubMed ID: 32027629
[TBL] [Abstract][Full Text] [Related]
10. Co-administration of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine does not interfere with the immune response to antigens contained in infant vaccines routinely used in the United States.
Marshall GS; Marchant CD; Blatter M; Friedland LR; Aris E; Miller JM
Hum Vaccin; 2011 Feb; 7(2):258-64. PubMed ID: 21307655
[TBL] [Abstract][Full Text] [Related]
11. Impact of maternal diphtheria-tetanus-acellular pertussis vaccination on pertussis booster immune responses in toddlers: Follow-up of a randomized trial.
Martinón-Torres F; Halperin SA; Nolan T; Tapiéro B; Perrett KP; de la Cueva IS; García-Sicilia J; Stranak Z; Vanderkooi OG; Kosina P; Rumlarova S; Virta M; Arribas JMM; Miranda-Valdivieso M; Novas BA; Bozensky J; Ortega MJC; Amador JTR; Baca M; Palomino EE; Zuccotti GV; Janota J; Marchisio PG; Kostanyan L; Meyer N; Ceregido MA; Cheuvart B; Kuriyakose SO; Mesaros N
Vaccine; 2021 Mar; 39(11):1598-1608. PubMed ID: 33612341
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial.
Guerra FA; Blatter MM; Greenberg DP; Pichichero M; Noriega FR;
Pediatrics; 2009 Jan; 123(1):301-12. PubMed ID: 19117896
[TBL] [Abstract][Full Text] [Related]
13. A fully liquid diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis--Haemophilus influenzae type b conjugate vaccine: immunogenicity and safety of primary vaccination in Taiwanese infants.
Lin TY; Wang YH; Chang LY; Huang YC; Kao HT; Lin PY; Lu HK; Chavand P; Ortiz E
Int J Infect Dis; 2007 Mar; 11(2):129-36. PubMed ID: 16762579
[TBL] [Abstract][Full Text] [Related]
14. Impact of a pentavalent combination vaccine on immunization timeliness in a state Medicaid population.
Happe LE; Lunacsek OE; Kruzikas DT; Marshall GS
Pediatr Infect Dis J; 2009 Feb; 28(2):98-101. PubMed ID: 19148039
[TBL] [Abstract][Full Text] [Related]
15. Epidemiology of pertussis and Haemophilus influenzae type b disease in Canada with exclusive use of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b pediatric combination vaccine and an adolescent-adult tetanus-diphtheria-acellular pertussis vaccine: implications for disease prevention in the United States.
Greenberg DP; Doemland M; Bettinger JA; Scheifele DW; Halperin SA; ; Waters V; Kandola K
Pediatr Infect Dis J; 2009 Jun; 28(6):521-8. PubMed ID: 19436236
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a fully-liquid DTaP-IPV-Hib-HepB vaccine (Vaxelis™) in premature infants.
Wilck MB; Xu ZJ; Stek JE; Lee AW
Hum Vaccin Immunother; 2021 Jan; 17(1):191-196. PubMed ID: 32750261
[No Abstract] [Full Text] [Related]
17. DTaP-IPV/Hib vaccine (Pentacel).
Dhillon S; Keam SJ
Paediatr Drugs; 2008; 10(6):405-16. PubMed ID: 18998751
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of a DTaP-IPV/Hib pentavalent vaccine given as primary and booster vaccinations in healthy infants and toddlers in Japan.
Nakayama T; Vidor E; Tsuzuki D; Nishina S; Sasaki T; Ishii Y; Mizukami H; Tsuge H
J Infect Chemother; 2020 Jul; 26(7):651-659. PubMed ID: 32307307
[TBL] [Abstract][Full Text] [Related]
19. Diminution of the anti-polyribosylribitol phosphate response to a combined diphtheria-tetanus-acellular pertussis/Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccination.
Rennels MB; Englund JA; Bernstein DI; Losonsky GA; Anderson EL; Pichichero ME; Munoz FM; Wolff MC
Pediatr Infect Dis J; 2000 May; 19(5):417-23. PubMed ID: 10819337
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of a pentavalent diphtheria, tetanus, pertussis, hepatitis B and polio combination vaccine in infants.
Yeh SH; Ward JI; Partridge S; Marcy SM; Lee H; Jing J; Curry ES; Howe BJ
Pediatr Infect Dis J; 2001 Oct; 20(10):973-80. PubMed ID: 11642632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
